Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study
Christiansen,S. N.,Horskjaer Rasmussen,S.,Ostergaard,M.,Pons,M.,Michelsen,B.,Pavelka,K.,Codreanu,C.,Ciurea,A.,Glintborg,B.,Santos,M. J.,Sari,I.,Rotar,Z.,Gudbjornsson,B.,Macfarlane,G. J.,Relas,H.,Iannone,F.,Laas,K.,Wallman,J. K.,van de Sande,M.,Provan,S. A.,Castrejon,I.,Zavada,J.,Mogosan,C.,Nissen,M. J.,Loft,A. G.,Barcelos,A.,Erez,Y.,Pirkmajer,K. P.,Grondal,G.,Jones,G. T.,Hokkanen,A.-M.,Chimenti,M. S.,Vorobjov,S.,Di Giuseppe,D.,Kvien,T. K.,Otero-Varela,L.,van der Horst-Bruinsma,I.,Hetland,M. L.,Ornbjerg,L. M.
DOI: https://doi.org/10.1136/rmdopen-2024-004166
2024-07-26
RMD Open
Abstract:Objectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries. Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0–10), for example, pain ≤2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated. Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/adjusted for multiple confounders). Results Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar. During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%). However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates. Conclusion Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.
rheumatology